AvenCell Therapeutics is a clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, targeting difficult-to-treat cancers such as acute myeloid leukemia (AML). The company aims to create allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct for complete control and target redirection of T cells post-infusion.
Market
Cell Therapy
Location
Watertown,
Massachusetts,
USA
Coinvestors
Novo Holdings, F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, NYBC Ventures, Blackstone Life Sciences